Viking Therapeutics (VKTX) director Kelly-Gemmell reports insider status

Rhea-AI Filing Summary

Viking Therapeutics, Inc. reports that Dorothy Elizabeth Kelly-Gemmell is a director of the company, and she is not an officer or a ten percent owner. This initial insider report lists no equity holdings or transactions, serving mainly to document her status as a director-level reporting person.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Holding entries reported: 0

3 metrics

Buy transactions reported 0 BuyCount in transaction summary for this Form 3

Sell transactions reported 0 SellCount in transaction summary for this Form 3

Holding entries reported 0 holdingEntries in transaction summary for this Form 3

Key Terms

ten percent owner, derivative transactions

2 terms

ten percent owner regulatory

"Field is_ten_percent_owner is 0 for the reporting person"

derivative transactions financial

"Field derivativeTransactionCount is 0 in the transaction summary"

Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/07/2026 - 04:34 PM Accepted by SEC EDGAR 08/07/2026 - 04:33 PM Learn about SEC filing dates

FAQ

What does Viking Therapeutics (VKTX) Form 3 report about Dorothy Elizabeth Kelly-Gemmell?

It shows that Dorothy Elizabeth Kelly-Gemmell is a director of Viking Therapeutics, Inc., not an officer and not a ten percent owner. The filing functions as her initial insider ownership report without listing any specific equity holdings or transactions.

Is Dorothy Elizabeth Kelly-Gemmell a ten percent owner of Viking Therapeutics (VKTX)?

No. The Form 3 identifies Dorothy Elizabeth Kelly-Gemmell as a director and flags that she is not a ten percent owner of Viking Therapeutics, Inc. Her insider status is based on board service rather than large equity ownership.

Does the Viking Therapeutics (VKTX) Form 3 disclose any insider transactions?

No insider trades are disclosed. The transaction summary shows zero buy, sell, or derivative transactions and no holding entries for Dorothy Elizabeth Kelly-Gemmell, indicating the filing is limited to establishing her status as a reporting director.

Why is this Form 3 filing important for Viking Therapeutics (VKTX) investors?

It documents that Dorothy Elizabeth Kelly-Gemmell has become an SEC-reportable insider as a director of Viking Therapeutics, Inc. After this initial record, any future reportable trades or ownership changes by her will appear in subsequent Forms 4 or 5.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kelly-Gemmell Dorothy Elizabeth

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2026

3. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24

No securities are beneficially owned.

	/s/ Michael Morneau, as Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)